FY2026 Earnings Forecast for IOVA Issued By HC Wainwright

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Iovance Biotherapeutics in a report issued on Thursday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn ($0.40) per share for the year, up from their previous forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.05) EPS and FY2027 earnings at ($0.13) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The firm had revenue of $121.47 million during the quarter, compared to analyst estimates of $115.98 million. Iovance Biotherapeutics had a negative return on equity of 29.71% and a negative net margin of 58.20%. Iovance Biotherapeutics’s revenue was up 64.8% on a year-over-year basis.

Other equities research analysts have also recently issued research reports about the stock. Wells Fargo & Company lifted their price target on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 30th. TD Cowen boosted their price target on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 24th. The Goldman Sachs Group initiated coverage on shares of Iovance Biotherapeutics in a report on Thursday, September 24th. They issued a “buy” rating and a $15.00 price objective on the stock. Citigroup reaffirmed an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. Finally, Citizens Jmp lifted their target price on shares of Iovance Biotherapeutics from $8.00 to $12.00 and gave the stock a “market outperform” rating in a report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.80.

Iovance Biotherapeutics Trading Down 1.0%

Iovance Biotherapeutics stock opened at $8.09 on Monday. Iovance Biotherapeutics has a 1 year low of $2.08 and a 1 year high of $15.37. The company has a market cap of $3.74 billion, a PE ratio of -15.26 and a beta of 0.88. The company’s 50-day moving average is $11.38 and its two-hundred day moving average is $6.03.

Institutional Investors Weigh In On Iovance Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. NorthCrest Asset Manangement LLC grew its holdings in shares of Iovance Biotherapeutics by 5.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 13,735 shares of the biotechnology company’s stock worth $204,000 after buying an additional 707 shares in the last quarter. Arcataur Capital Management LLC raised its position in Iovance Biotherapeutics by 3.6% in the 3rd quarter. Arcataur Capital Management LLC now owns 28,600 shares of the biotechnology company’s stock valued at $424,000 after buying an additional 1,000 shares during the last quarter. Krilogy Financial LLC raised its position in Iovance Biotherapeutics by 6.6% in the 3rd quarter. Krilogy Financial LLC now owns 16,662 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 1,032 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in Iovance Biotherapeutics by 5.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 32,957 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 1,691 shares in the last quarter. Finally, Brighton Jones LLC lifted its stake in Iovance Biotherapeutics by 5.1% in the 3rd quarter. Brighton Jones LLC now owns 40,069 shares of the biotechnology company’s stock valued at $594,000 after acquiring an additional 1,954 shares in the last quarter. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient. The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.